List of Excipients in Branded Drug TRULANCE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Salix Pharmaceuticals Inc	TRULANCE	plecanatide	65649-003	CELLULOSE, MICROCRYSTALLINE	2034-06-05
Salix Pharmaceuticals Inc	TRULANCE	plecanatide	65649-003	MAGNESIUM STEARATE	2034-06-05
Synergy Pharmaceuticals Inc	TRULANCE	plecanatide	70194-003	CELLULOSE, MICROCRYSTALLINE	2034-06-05
Synergy Pharmaceuticals Inc	TRULANCE	plecanatide	70194-003	MAGNESIUM STEARATE	2034-06-05

TRULANCE Excipient Strategy and Commercial Opportunities

Last updated: September 5, 2026

Trulance contains plecanatide, a synthetic 16-amino-acid peptide approved in the United States for chronic idiopathic constipation and irritable bowel syndrome with constipation. Its marketed 3 mg tablet uses a conventional solid-dose excipient system: lactose monohydrate, microcrystalline cellulose, crospovidone and magnesium stearate. The formulation has a low technical barrier to manufacture, so commercial opportunities are more likely to arise from patient-friendly delivery formats, pediatric administration, lactose-free positioning, and differentiated generic or 505(b)(2) products than from basic tablet replication. [1]

What excipients are used in the Trulance formulation?

Trulance is an immediate-release, uncoated oral tablet containing 3 mg of plecanatide. The FDA prescribing information identifies four inactive ingredients:

Excipient	Primary formulation role	Commercial significance
Lactose monohydrate	Diluent and tablet-mass builder	Creates an opportunity for lactose-free alternatives
Microcrystalline cellulose	Diluent, dry binder and compression aid	Supports direct compression and tablet robustness
Crospovidone	Superdisintegrant	Promotes rapid tablet breakup
Magnesium stearate	Lubricant	Supports manufacturing ejection and tooling performance

The formulation is technically straightforward. It does not rely on an enteric coating, modified-release matrix, lipid vehicle, or complex delivery system. The product is therefore suitable for conventional high-speed tablet manufacturing, provided the manufacturer controls blend uniformity, peptide stability, compression force and lubrication time. [1]

The absence of a coating reduces process complexity and excipient cost. It also limits the number of obvious formulation-based differentiation points for a follow-on product.

How does plecanatide affect excipient selection?

Plecanatide is a peptide drug that acts locally in the intestinal lumen by activating guanylate cyclase-C. Systemic exposure is minimal. The formulation objective is therefore different from that of an orally absorbed peptide or a systemically delivered small molecule.

The key excipient priorities are:

1. Maintaining peptide chemical and physical stability during blending, compression and storage.
2. Producing rapid disintegration without excessive mechanical stress.
3. Avoiding moisture exposure that could accelerate degradation.
4. Preserving dose uniformity at the relatively low 3 mg drug load.
5. Supporting patient administration without requiring complex gastrointestinal protection.

A low-dose peptide tablet creates a content-uniformity challenge. Plecanatide must be distributed consistently through the excipient blend, even though the active ingredient represents a small fraction of total tablet mass. Geometric dilution, ordered mixing, low-shear blending and validated sampling plans are likely to be more important than the selection of an exotic excipient.

Which excipient properties matter most?

Microcrystalline cellulose and lactose provide the bulk of the tablet and support direct compression. Their particle-size distribution, density and moisture content can affect segregation and tablet weight variation.

Crospovidone is important because a rapid-disintegrating tablet is commercially useful for a drug intended to act locally in the gastrointestinal tract. Excessive compression force or over-lubrication can slow disintegration. Magnesium stearate concentration and blending time therefore require tight process control.

Because the active is a peptide, the developer should evaluate:

• Water activity and residual moisture.
• Excipient peroxide and aldehyde levels.
• Temperature and humidity stress.
• Compatibility with reducing sugars.
• Long-term assay, impurity and dissolution profiles.
• Container-closure protection against moisture.

Lactose is a reducing sugar. Although the marketed product uses lactose, a follow-on manufacturer may investigate lactose-related interaction risk under accelerated and long-term conditions, particularly if the alternative formulation changes moisture content, pH microenvironment or processing temperature.

What commercial opportunities exist for a Trulance excipient strategy?

The strongest opportunities are in differentiated delivery rather than simple excipient substitution.

Lactose-free and allergen-positioned tablets

A lactose-free version could replace lactose monohydrate with mannitol, dibasic calcium phosphate, anhydrous lactose alternatives, spray-dried cellulose systems or other direct-compression fillers. The commercial value would depend on demonstrated patient need, not merely on a different inactive-ingredient list.

A lactose-free formulation could support:

• A 505(b)(2) application with a differentiated label.
• A branded authorized generic strategy.
• A specialty-pharmacy product for patients with lactose intolerance concerns.
• A formulation license to an established generic manufacturer.

The substitution would require comparative dissolution, stability, tablet-strength and bioequivalence analysis. Since plecanatide has local gastrointestinal activity and limited systemic exposure, conventional plasma bioequivalence may not fully capture every formulation difference. FDA would determine the applicable equivalence approach.

Pediatric dosage forms

The pediatric market is a significant formulation opportunity because young patients may have difficulty swallowing conventional tablets. FDA labeling now includes pediatric use information for chronic idiopathic constipation in patients aged 6 years and older. [1]

Potential formats include:

• Mini-tablets.
• Orally disintegrating tablets.
• Granules or sprinkle products.
• Powder for constitution in water.
• Sachets for unit-dose administration.
• Taste-masked multiparticulates.

The principal technical challenge is taste. Plecanatide acts in the gastrointestinal tract, so taste masking must not compromise dose recovery or create unacceptable interactions with food and beverage vehicles. A multiparticulate system could separate taste-masking technology from the release of the active in the intestine.

Pediatric products also create opportunities for age-appropriate dosing flexibility. The marketed 3 mg strength may not provide adequate dose flexibility for all pediatric populations, depending on the approved dosing instructions and clinical development strategy.

Administration through alternative routes

A formulation that can be dispersed in water or administered through a feeding tube could address patients with dysphagia, institutional-care needs or enteral feeding requirements. Such a product would require testing of:

• Dispersion time.
• Recovery from administration devices.
• Tube compatibility.
• Adsorption to tubing materials.
• Stability after reconstitution.
• Dose uniformity after settling.
• Compatibility with common enteral nutrition products.

A tube-compatible formulation could create a differentiated 505(b)(2) product if the label supports a clinically meaningful administration benefit.

Orally disintegrating and fast-dispersing tablets

An orally disintegrating tablet could improve ease of use without requiring systemic absorption. Excipients such as mannitol, crospovidone, low-substituted hydroxypropyl cellulose and specialized co-processed fillers may support rapid dispersion.

The product would need a taste-masking strategy. Sweeteners, flavors and polymer coatings could affect product acceptability, but any coating or complexation approach must preserve the local activity of plecanatide and meet dissolution requirements.

How does a generic Trulance strategy compare with a 505(b)(2) strategy?

A conventional ANDA would generally target the reference product’s dosage form, strength, route of administration and active ingredient. A formulation using the same qualitative and quantitative excipients, or a sufficiently similar excipient system, could simplify development but would provide limited commercial differentiation.

Strategy	Main benefit	Main limitation	Commercial use
Conventional ANDA	Lower development burden if equivalence is straightforward	Price competition and limited differentiation	Commodity generic
Lactose-free ANDA or differentiated generic	Addresses excipient intolerance concerns	May require additional equivalence and stability work	Premium generic or authorized generic
505(b)(2) pediatric product	Supports new dosage form or administration claim	Requires additional clinical or bridging evidence	Specialty product
Orally disintegrating tablet	Improves swallowing convenience	Taste masking and mechanical robustness	Brand extension
Sprinkle or sachet product	Supports pediatric and dysphagia use	Reconstitution and dose-recovery validation	Hospital, pediatric and long-term-care channels
Tube-compatible formulation	Serves enteral-feeding patients	Device and administration compatibility testing	Institutional and specialty markets

A basic excipient change alone is unlikely to create a durable commercial moat. The stronger route is to connect the excipient design to an approved administration advantage.

What patents protect Trulance and its formulation?

Trulance is covered by a patent estate associated with plecanatide and guanylate cyclase-C agonist technology. Public patent records identify U.S. patents assigned to Synergy Pharmaceuticals or related entities covering plecanatide compounds and therapeutic uses. A commonly cited composition patent is U.S. Patent No. 8,637,655, which has an expected expiration in the early 2030s, subject to patent-term adjustment, terminal disclaimers and any applicable extension. [2]

The relevant IP categories include:

• Plecanatide compound claims.
• Peptide sequence and analog claims.
• Treatment of constipation.
• Treatment of IBS-C.
• Dosing and administration claims.
• Pharmaceutical composition claims.
• Manufacturing and purification claims.

The commercial risk depends on the current FDA Orange Book listings and the claims remaining enforceable after litigation, prosecution history and any settlement. Orange Book entries can change through patent expiration, delisting, corrections and new listings. [3]

Does an excipient substitution avoid patent infringement?

Not necessarily. A product can avoid a narrow formulation claim while still infringing compound, method-of-use or composition claims. An excipient change does not remove the active ingredient from the scope of a plecanatide composition patent.

A follow-on developer would need to separate:

• Active-ingredient claim risk.
• Method-of-use claim risk.
• Formulation-claim risk.
• Manufacturing-process claim risk.
• Regulatory exclusivity risk.
• Patent-term and pediatric-extension risk.

What is the Orange Book and FDA regulatory status of Trulance?

Trulance was approved by FDA in January 2017 under NDA 208745 for chronic idiopathic constipation in adults. FDA later expanded the product’s indication to IBS-C in adults. The product is marketed by Salix Pharmaceuticals, a subsidiary of Bausch Health Companies. [1,4]

The FDA regulatory pathway is an NDA-based pathway. Trulance is not a biologic and does not create a conventional biosimilar pathway. A competitor would generally pursue an ANDA if it can demonstrate pharmaceutical equivalence and bioequivalence, or a 505(b)(2) application for a materially different dosage form, formulation, route or administration method.

Is Trulance exposed to biosimilar competition?

No. Plecanatide is a synthetic peptide drug rather than a biologic licensed under the Public Health Service Act. Competitive pressure would come from generic or hybrid products, not biosimilars.

Which companies are likely to challenge Trulance?

The likely challengers are large generic manufacturers with peptide, oral solid-dose and gastrointestinal portfolios. Potential participants in a competitive market include Teva, Viatris, Sandoz, Amneal, Lupin, Dr. Reddy’s Laboratories, Sun Pharma and privately held specialty-generic manufacturers.

A Paragraph IV challenge would be the principal mechanism for contesting listed patents before expiry. The commercial impact would depend on:

• The number of ANDA filers.
• Whether a first filer obtains 180-day exclusivity.
• The scope of asserted patents.
• The availability of a pediatric or differentiated 505(b)(2) product.
• The terms of any settlement with the patent holder.

No reliable conclusion about current Paragraph IV litigation or settlement terms should be drawn without the contemporaneous FDA litigation records and Orange Book data.

How strong is the Trulance patent estate?

The estate is strongest against an unmodified generic that uses plecanatide for the same approved indications before core compound or use patents expire. It is weaker as a barrier to non-infringing delivery innovations after core patents expire, particularly if a competitor develops a different dosage form and obtains an independent label.

The principal barriers are likely to be:

• Core plecanatide composition claims.
• Method-of-use claims for constipation and IBS-C.
• Regulatory exclusivity and pediatric protections.
• Manufacturing know-how around peptide purity and stability.

Excipient selection alone is unlikely to determine freedom to operate. The active ingredient, indication, timing and manufacturing route are more consequential.

What manufacturing and IP barriers affect commercial entry?

Plecanatide manufacturing may require controlled peptide synthesis, purification, impurity characterization and low-moisture drug-product processing. A generic tablet manufacturer may need to source qualified plecanatide API from an approved or technically capable supplier.

Key barriers include:

• API supply qualification.
• Peptide-related impurity control.
• Low-dose content uniformity.
• Moisture-sensitive stability programs.
• Scale-up of direct compression.
• Analytical methods for related substances.
• Demonstration of dissolution and bioequivalence.
• Protection against cross-contamination in multiproduct facilities.

For excipient suppliers, the opportunity is more attractive where the excipient provides a measurable manufacturing benefit, such as improved flow, lower moisture, faster disintegration or better content uniformity. A standard replacement of lactose with another filler is less defensible commercially unless linked to a regulatory or patient-use advantage.

Key Takeaways

• Trulance uses a conventional tablet formulation containing lactose monohydrate, microcrystalline cellulose, crospovidone and magnesium stearate.
• The product has a low-complexity excipient platform and limited formulation differentiation in its marketed form.
• The most credible commercial opportunities are lactose-free products, pediatric mini-tablets, orally disintegrating tablets, sprinkle formulations and tube-compatible dosage forms.
• Plecanatide is not subject to biosimilar competition. Generic and 505(b)(2) pathways are more relevant.
• Excipient substitution does not by itself avoid plecanatide compound, method-of-use or composition patent claims.
• A differentiated delivery system tied to an FDA-recognized administration benefit offers stronger commercial protection than a simple filler substitution.
• Manufacturing value is concentrated in peptide impurity control, low-dose uniformity, moisture management and API supply.

FAQs

Can lactose be removed from a Trulance generic?

Yes. Lactose monohydrate can potentially be replaced with a non-lactose diluent, but the product would require appropriate stability, dissolution, content-uniformity and bioequivalence support.

Is plecanatide stable in standard tablet excipients?

The marketed formulation demonstrates compatibility with lactose monohydrate, microcrystalline cellulose, crospovidone and magnesium stearate. Alternative excipients require independent compatibility and stability testing.

Is an orally disintegrating Trulance tablet commercially attractive?

Potentially. The format could address swallowing difficulty and pediatric administration, but taste masking and dose recovery would be central development issues.

Can Trulance be developed as a biosimilar?

No. Plecanatide is regulated as a synthetic peptide drug, not as a biologic eligible for the biosimilar pathway.

What is the best excipient opportunity for a Trulance follow-on product?

A lactose-free, rapidly disintegrating or pediatric-friendly platform linked to a differentiated administration claim is more commercially defensible than a routine excipient substitution.

References

1. U.S. Food and Drug Administration. (2024). Trulance (plecanatide) tablets, prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/

2. United States Patent and Trademark Office. (2014). U.S. Patent No. 8,637,655, guanylate cyclase receptor agonists. https://patents.google.com/patent/US8637655

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. Food and Drug Administration. (2017). FDA approves Trulance for chronic idiopathic constipation. https://www.fda.gov/drugs/resources-information-approved-drugs/ FDA approves Trulance for chronic idiopathic constipation.